Journal of Ginseng Research

The Korean Society of Ginseng (고려인삼학회)
권호 표지
DOI QR코드

DOI QR Code

Medicinal potential of Panax ginseng and its ginsenosides in atopic dermatitis treatment

  • Lorz, Laura Rojas (Department of Integrative Biotechnology, Sungkyunkwan University) ;
  • Kim, Mi-Yeon (School of Systems Biomedical Science, Soongsil University) ;
  • Cho, Jae Youl (Department of Integrative Biotechnology, Sungkyunkwan University)
  • Received : 2018.12.07
  • Accepted : 2018.12.31
  • Published : 2020.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Atopic dermatitis (AD) is a chronic and relapsing inflammatory disease that affects 1%-20% of people worldwide. Despite affecting many people, AD current treatments, such as corticosteroids and calcineurin inhibitors, have not only harmful secondary effects but are also often ineffective. Therefore, natural nontoxic compounds are on high demand for developing new effective AD treatments. Panax ginseng Meyer has been used traditionally for its promising healing and restorative properties to treat many diseases including skin disorders, reason why in this review we want to explore the research performed with AD and P. ginseng as well as determining its potential for new drug development. Previous researches have shown that P. ginseng has positive effects in AD patients such as lower eczema area and severity index, transepidermal water loss, and immunoglobulin E levels and better quality of sleep. In vivo animal models, as well, have shown positive results to P. ginseng and derived ginsenosides, such as the decrease of transepidermal water loss, immunoglobulin E levels in serum, allergy-related cytokines, and downregulation of NF-κB, MAPK, and Ikaros pathways. All of these previous data suggest that P. ginseng and its derived ginsenosides are undoubtedly a nontoxic effective option to treat AD.

Keywords

References

  1. Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res 2016;8:181-90. https://doi.org/10.4168/aair.2016.8.3.181
  2. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase three. J Allergy Clin Immunol 2009;124. 1251-1258.e1223. https://doi.org/10.1016/j.jaci.2009.10.009
  3. Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy 2014;2014. 354250-354250. https://doi.org/10.1155/2014/354250
  4. Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol 2017;5:1519-31. https://doi.org/10.1016/j.jaip.2017.08.005
  5. Park HJ, Kim DH, Park SJ, Kim JM, Ryu JH. Ginseng in traditional herbal prescriptions. J Ginseng Res 2012;36:225-41. https://doi.org/10.5142/jgr.2012.36.3.225
  6. Kimura Y, Sumiyoshi M, Sakanaka M. Effects of ginsenoside $Rb_{1}$ on skin changes. J Biomed Biotechnol 2012;2012. 946242-946242.
  7. Nowicki R, Nowicki R, Trzeciak M, Wilkowska A, sokolowska-wojdylo M, Lugowska-Umer H, Baranska-Rybak W, Kaczmarski M, Kowalewski C, Kruszewski J, et al. Special paper atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section. Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology; 2015.
  8. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 2013;68:974-82. https://doi.org/10.1111/all.12184
  9. Egawa G, Kabashima K. Barrier dysfunction in the skin allergy. Allergol Int 2018;67:3-11. https://doi.org/10.1016/j.alit.2017.10.002
  10. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2011;2:110.
  11. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plotz S, Knol EF, Kapp A, et al. Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-6. https://doi.org/10.1111/j.1398-9995.2005.00791.x
  12. Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy 2018;73:29-36. https://doi.org/10.1111/all.13239
  13. De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol 2009;129:14-30. https://doi.org/10.1038/jid.2008.259
  14. Cesare AD, Meglio PD, Nestle FO. A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol 2008;128:2569-71. https://doi.org/10.1038/jid.2008.283
  15. Kee J-Y, Jeon Y-D, Kim D-S, Han Y-H, Park J, Youn D-H, Kim S-J, Ahn KS, Um JY, Hong S-H. Korean red ginseng improves atopic dermatitis-like skin lesions by suppressing expression of proinflammatory cytokines and chemokines in vivo and in vitro. J Ginseng Res 2017;41:134-43. https://doi.org/10.1016/j.jgr.2016.02.003
  16. Bae E-A, Han MJ, Shin Y-W, Kim D-H. Inhibitory effects of Korean red ginseng and its genuine constituents ginsenosides Rg3, Rf, and Rh2 in mouse passive cutaneous anaphylaxis reaction and contact dermatitis models. Biol Pharmaceut Bull 2006;29:1862-7. https://doi.org/10.1248/bpb.29.1862
  17. Sohn E-H, Jang S-A, Lee C-H, Jang K-H, Kang S-C, Park H-J, Pyo S. Effects of Korean red ginseng extract for the treatment of atopic dermatitis-like skin lesions in mice. J Ginseng Res 2011;35:479-86. https://doi.org/10.5142/jgr.2011.35.4.479
  18. McPherson T. Current understanding in pathogenesis of atopic dermatitis. Indian J Dermatol 2016;61:649-55. https://doi.org/10.4103/0019-5154.193674
  19. Kawasaki H, Kubo A, Sasaki T, Amagai M. Loss-of-function mutations within the Filaggrin gene and atopic dermatitis.
  20. Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int 2011;60:1-9. https://doi.org/10.2332/allergolint.10-RAI-0270
  21. Leung DYM, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 2014;134:769-79. https://doi.org/10.1016/j.jaci.2014.08.008
  22. Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, Shigematsu Y, Yoshida K, Niizeki H, Motomura K-i, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol 2014;134. 824-830.e826. https://doi.org/10.1016/j.jaci.2014.07.060
  23. Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WHI, Brown SJ, Chen Z, Chen Y, Williams HC. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014;134:818-23. https://doi.org/10.1016/j.jaci.2014.08.005
  24. Suarez AL, Feramisco JD, Koo J, Steinhoff M. Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates. Acta Derm Venereol 2012;92:7-15. https://doi.org/10.2340/00015555-1188
  25. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol 2016;51:263-92. https://doi.org/10.1007/s12016-015-8488-5
  26. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, Bergman JN, Chamlin SL, Cohen DE, Cooper KD, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014;71:116-32. https://doi.org/10.1016/j.jaad.2014.03.023
  27. He A, Feldman SR, Fleischer AB. An assessment of the use of antihistamines in the management of atopic dermatitis. J Am Acad Dermatol 2018;79:92-6. https://doi.org/10.1016/j.jaad.2017.12.077
  28. Mooney E, Rademaker M, Dailey R, Daniel BS, Drummond C, Fischer G, Foster R, Grills C, Halbert A, Hill S, et al. Adverse effects of topical corticosteroids in paediatric eczema: australasian consensus statement. Australas J Dermatol 2015;56:241-51. https://doi.org/10.1111/ajd.12313
  29. El-Batawy MMY, Bosseila MAW, Mashaly HM, Hafez VSGA. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2009;54:76-87. https://doi.org/10.1016/j.jdermsci.2009.02.002
  30. Taylor K, Swan DJ, Affleck A, Flohr C, Reynolds NJ, Dermatology UKTRNi, the UKDCTN. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol 2017;176:1617-23. https://doi.org/10.1111/bjd.15235
  31. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001;357:2012-6. https://doi.org/10.1016/S0140-6736(00)05114-X
  32. Goujon C, Viguier M, Staumont-Salle D, Bernier C, Guillet G, Lahfa M, Ferrier Le Bouedec M-C, Cambazard F, Bottigioli D, Grande S, et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a Phase III randomized noninferiority trial. J Allergy Clin Immunol 2018;6. 562-569.e563. https://doi.org/10.1016/j.jaip.2017.07.007
  33. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014;71:327-49. https://doi.org/10.1016/j.jaad.2014.03.030
  34. Lee H-H, Song I-H, Friedrich M, Gauliard A, Detert J, Rowert J, Audring H, Kary S, Burmester G-R, Sterry W, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-a antagonists. Br J Dermatol 2007;156:486-91. https://doi.org/10.1111/j.1365-2133.2007.07682.x
  35. Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-Roldan F, Paravisini A, Sanchez-Ramon S, Suarez Fernandez R. Omalizumab for the treatment of atopic dermatitis. Actas Dermo-Sifiliograficas (English Edition) 2012;103:624-8. https://doi.org/10.1016/j.adengl.2012.08.002
  36. SimpsonEL, Bieber T,Guttman-Yassky E, Beck LA, Blauvelt A,CorkMJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour J-P, et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Eng J Med 2016;375:2335-48. https://doi.org/10.1056/NEJMoa1610020
  37. Kim EH, Kim W. An insight into ginsenoside metabolite compound K as a potential tool for skin disorder. Evidence-based complementary and alternative medicine. eCAM 2018;2018. 8075870-8075870.
  38. Sarvenaz S-R, Sara S-R, Amirhossein S, Zahra T-N. Ginseng in dermatology: a review. Cur Pharmaceut Des 2017;23:1649-66. https://doi.org/10.2174/1381612822666161021152322
  39. Kim H, Park CW, Cho SH. The beneficial effect of Korean red ginseng extract on atopic dermatitis patients: an 8 weeks open, noncomparative clinical study. Ann Dermatol 2018;30:304-8. https://doi.org/10.5021/ad.2018.30.3.304
  40. Lee KG, Son SW. Efficacy of korean red ginseng in the treatment of atopic dermatitis. J Ginseng Res 2011;35:149-54. https://doi.org/10.5142/jgr.2011.35.2.149
  41. Cho E, Cho SH. Effects of Korean red ginseng extract on the prevention of atopic dermatitis and its mechanism on early lesions in a murine model. J Ethnopharmacol 2013;145:294-302. https://doi.org/10.1016/j.jep.2012.11.006
  42. Lee HJ, Cho SH. Therapeutic effects of Korean red ginseng extract in a murine model of atopic dermatitis: anti-pruritic and anti-inflammatory mechanism. J Kor Med Sci 2017;32:679-87. https://doi.org/10.3346/jkms.2017.32.4.679
  43. Samukawa K, Izumi Y, Shiota M, Nakao T, Osada-Oka M, Miura K, Iwao H. Red ginseng inhibits scratching behavior associated with atopic dermatitis in experimental animal models. J Pharmacol Sci 2012;118:391-400. https://doi.org/10.1254/jphs.11182FP
  44. Choi JH, Jin SW, Park BH, Kim HG, Khanal T, Han HJ, Hwang YP, Choi JM, Chung YC, Hwang SK, et al. Cultivated ginseng inhibits 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice and $TNF-{\alpha}/IFN-{\gamma}-induced$ TARC activation in HaCaT cells. Food Chem Toxicol 2013;56:195-203. https://doi.org/10.1016/j.fct.2013.02.037
  45. Lee B-H, Kim H-K, Jang M, Kim H-J, Choi S-H, Hwang S-H, Kim H-C, Rhim H, Cho I-H, Nah S-Y. Effects of gintonin-enriched fraction in an atopic dermatitis animal model: involvement of autotaxin regulation. Biol Pharmaceut Bull 2017;40:1063-70. https://doi.org/10.1248/bpb.b17-00124
  46. Kim JR, Choi J, Kim J, Kim H, Kang H, Kim EH, Chang J-H, Kim Y-E, Choi YJ, Lee KW, et al. 20-O-${\beta}$-d-glucopyranosyl-20(S)-protopanaxadiol-fortified ginseng extract attenuates the development of atopic dermatitis-like symptoms in NC/Nga mice. J Ethnopharmacol 2014;151:365-71. https://doi.org/10.1016/j.jep.2013.10.058
  47. Osada-Oka M, Hirai S, Izumi Y, Misumi K, Samukawa K, Tomita S, Miura K, Minamiyama Y, Iwao H. Red ginseng extracts attenuate skin inflammation in atopic dermatitis through p70 ribosomal protein S6 kinase activation. J Pharmacol Sci 2018;136:9-15. https://doi.org/10.1016/j.jphs.2017.11.002
  48. Wang H-H, Li Y-C, Huang Y-C. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2016;138. 1719-1722.e1711. https://doi.org/10.1016/j.jaci.2016.05.038

Cited by

  1. Effects of four new processing technologies on pesticide residues and saponins content in ginseng vol.44, pp.7, 2020, https://doi.org/10.1111/jfpp.14537
  2. Antioxidative and Skin Protective Effects of Canarium subulatum Methanol Extract on Keratinocytes vol.2021, 2021, https://doi.org/10.1155/2021/6692838
  3. Comparative Study on Different Skin Pruritus Mouse Models vol.8, 2020, https://doi.org/10.3389/fmed.2021.630237
  4. TAK1/AP-1-Targeted Anti-Inflammatory Effects of Barringtonia augusta Methanol Extract vol.26, pp.10, 2020, https://doi.org/10.3390/molecules26103053
  5. Anti-Inflammatory Activity of a Medicinal Herb Extract Mixture, HM-V, on an Animal Model of DNCB-Induced Chronic Skin Inflammation vol.10, pp.8, 2020, https://doi.org/10.3390/plants10081546